Literature DB >> 19794140

In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance.

Andrea Annoni1, Brian D Brown, Alessio Cantore, Lucia Sergi Sergi, Luigi Naldini, Maria-Grazia Roncarolo.   

Abstract

We previously showed that incorporating target sequences for the hematopoietic-specific microRNA miR-142 into an antigen-encoding transgene prevents antigen expression in antigen-presenting cells (APCs). To determine whether this approach induces immunologic tolerance, we treated mice with a miR-142-regulated lentiviral vector encoding green fluorescent protein (GFP), and subsequently vaccinated the mice against GFP. In contrast to control mice, no anti-GFP response was observed, indicating that robust tolerance to the transgene-encoded antigen was achieved. Furthermore, injection of the miR-142-regulated vector induced a population of GFP-specific regulatory T cells. Interestingly, an anti-GFP response was observed when microRNA miR-122a was inserted into the vector and antigen expression was detargeted from hepatocytes as well as APCs. This demonstrates that, in the context of lentiviral vector-mediated gene transfer, detargeting antigen expression from professional APCs, coupled with expression in hepatocytes, can induce antigen-specific immunologic tolerance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19794140      PMCID: PMC2792211          DOI: 10.1182/blood-2009-04-214569

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

Review 1.  Dendritic cells and the control of immunity.

Authors:  J Banchereau; R M Steinman
Journal:  Nature       Date:  1998-03-19       Impact factor: 49.962

2.  Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle.

Authors:  Y Yang; S E Haecker; Q Su; J M Wilson
Journal:  Hum Mol Genet       Date:  1996-11       Impact factor: 6.150

3.  Hepatocytes induce functional activation of naive CD8+ T lymphocytes but fail to promote survival.

Authors:  P Bertolino; M C Trescol-Biémont; C Rabourdin-Combe
Journal:  Eur J Immunol       Date:  1998-01       Impact factor: 5.532

4.  Hepatocytes express abundant surface class I MHC and efficiently use transporter associated with antigen processing, tapasin, and low molecular weight polypeptide proteasome subunit components of antigen processing and presentation pathway.

Authors:  Ming Chen; Piotr Tabaczewski; Steven M Truscott; Luc Van Kaer; Iwona Stroynowski
Journal:  J Immunol       Date:  2005-07-15       Impact factor: 5.422

5.  Major role of local immune responses in antibody formation to factor IX in AAV gene transfer.

Authors:  L Wang; O Cao; B Swalm; E Dobrzynski; F Mingozzi; R W Herzog
Journal:  Gene Ther       Date:  2005-10       Impact factor: 5.250

6.  Induction of cytokine production in naive CD4(+) T cells by antigen-presenting murine liver sinusoidal endothelial cells but failure to induce differentiation toward Th1 cells.

Authors:  P A Knolle; E Schmitt; S Jin; T Germann; R Duchmann; S Hegenbarth; G Gerken; A W Lohse
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

7.  Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis.

Authors:  H L Weiner; G A Mackin; M Matsui; E J Orav; S J Khoury; D M Dawson; D A Hafler
Journal:  Science       Date:  1993-02-26       Impact factor: 47.728

Review 8.  Immune therapy for autoimmune diseases.

Authors:  Lawrence Steinman
Journal:  Science       Date:  2004-07-09       Impact factor: 47.728

9.  Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice.

Authors:  Antonia Follenzi; Manuela Battaglia; Angelo Lombardo; Andrea Annoni; Maria Grazia Roncarolo; Luigi Naldini
Journal:  Blood       Date:  2003-12-30       Impact factor: 22.113

10.  Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis.

Authors:  K Ando; T Moriyama; L G Guidotti; S Wirth; R D Schreiber; H J Schlicht; S N Huang; F V Chisari
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

View more
  59 in total

Review 1.  Endogenous migration modulators as parent compounds for the development of novel cardiovascular and anti-inflammatory drugs.

Authors:  Wolfgang Poller; Madlen Rother; Carsten Skurk; Carmen Scheibenbogen
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A.

Authors:  Hideto Matsui; Carol Hegadorn; Margareth Ozelo; Erin Burnett; Angie Tuttle; Andrea Labelle; Paul B McCray; Luigi Naldini; Brian Brown; Christine Hough; David Lillicrap
Journal:  Mol Ther       Date:  2011-02-01       Impact factor: 11.454

3.  Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.

Authors:  Jonathan D Finn; Margareth C Ozelo; Denise E Sabatino; Helen W G Franck; Elizabeth P Merricks; Julie M Crudele; Shangzhen Zhou; Haig H Kazazian; David Lillicrap; Timothy C Nichols; Valder R Arruda
Journal:  Blood       Date:  2010-09-28       Impact factor: 22.113

Review 4.  Integration-deficient lentiviral vectors: a slow coming of age.

Authors:  Klaus Wanisch; Rafael J Yáñez-Muñoz
Journal:  Mol Ther       Date:  2009-06-02       Impact factor: 11.454

Review 5.  Inhibitors - cellular aspects and novel approaches for tolerance.

Authors:  D W Scott
Journal:  Haemophilia       Date:  2014-05       Impact factor: 4.287

6.  miRNA-mediated silencing in hepatocytes can increase adaptive immune responses to adenovirus vector-delivered transgenic antigens.

Authors:  Matthias W Kron; Sigrid Espenlaub; Tatjana Engler; Reinhold Schirmbeck; Stefan Kochanek; Florian Kreppel
Journal:  Mol Ther       Date:  2011-05-10       Impact factor: 11.454

7.  Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery.

Authors:  C Goyvaerts; Y De Vlaeminck; D Escors; S Lienenklaus; M Keyaerts; G Raes; K Breckpot
Journal:  Gene Ther       Date:  2017-05-25       Impact factor: 5.250

8.  Pigmy MicroRNA: surveillance cops in Therapies kingdom.

Authors:  Utpal Bhadra; Pradipta Patra; Jagamohan Chhatai; Manika Pal-Bhadra
Journal:  Mol Med       Date:  2016-09-28       Impact factor: 6.354

9.  Portal vein delivery of viral vectors for gene therapy for hemophilia.

Authors:  Alexandra Sherman; Alexander Schlachterman; Mario Cooper; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Roland W Herzog; Timothy C Nichols
Journal:  Methods Mol Biol       Date:  2014

Review 10.  Antigen-specific immunotherapy of autoimmune and allergic diseases.

Authors:  Catherine A Sabatos-Peyton; Johan Verhagen; David C Wraith
Journal:  Curr Opin Immunol       Date:  2010-09-17       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.